Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer

World Journal of Surgical Oncology

Research

Yongrui Wang¹  Tingcui Zhang²  Keli Su³  Guijun Hao³ 

[1] Department of Clinical Laboratory, The Fourth People’s Hospital of Jinan, 250031, Jinan, Shandong Province, China;Department of Internal Medicine, The Central Hospital of Jinan, 250012, Jinan, Shandong Province, China;Department of Oncology, The Fourth People’s Hospital of Jinan, NO. 50, Shifan Road, 250031, Jinan, Shandong Province, China;

关键词: miRNAs;    Biological markers;    Non-small cell lung cancer;    Diagnosis;    Prognosis;   

DOI  :  10.1186/s12957-016-0980-8

 received in 2016-04-19, accepted in 2016-08-13,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundRecently, circulating microRNAs (miRNAs) have been reported to be stably detectable in plasma/serum and to function as potent biomarkers in various cancers. The aim of this study was to evaluate the expression level of plasma miRNA-195 in patients with non-small cell lung cancer (NSCLC) and investigate its diagnostic and prognostic value.MethodsQuantitative real-time PCR was performed to evaluate plasma miRNA-195 levels in 100 NSCLC patients and 100 healthy volunteers. The association between miRNA-195 expression and clinicopathological factors as well as the overall survival was analyzed. Receiver-operating characteristic (ROC) curve analysis was carried out to assess the potential value of plasma miRNA-195 for NSCLC diagnosis.ResultsPlasma miRNA-195 was downregulated in NSCLC patients compared with healthy controls (P < 0.001). Decreased plasma miRNA-195 expression was significantly associated with lymph node metastasis and advanced clinical stage. ROC curve analysis showed that plasma miRNA-195 was a useful marker for NSCLC diagnosis. Multivariate Cox regression analysis confirmed low plasma miRNA-195 expression as an independent unfavorable prognostic factor for NSCLC patients.ConclusionsThese findings indicate that plasma miRNA-195 might serve as a promising biomarker for the early detection and prognosis evaluation of NSCLC.

【 授权许可】

CC BY   
© The Author(s). 2016